keyword
https://read.qxmd.com/read/38646638/hypofractionated-radiotherapy-combined-with-lenalidomide-improves-systemic-antitumor-activity-in-mouse-solid-tumor-models
#1
JOURNAL ARTICLE
Kateryna Onyshchenko, Ren Luo, Xi Rao, Xuanwei Zhang, Simone Gaedicke, Anca-Ligia Grosu, Elke Firat, Gabriele Niedermann
Background: Hypofractionated radiotherapy (hRT) can induce a T cell-mediated abscopal effect on non-irradiated tumor lesions, especially in combination with immune checkpoint blockade (ICB). However, clinically, this effect is still rare, and ICB-mediated adverse events are common. Lenalidomide (lena) is an anti-angiogenic and immunomodulatory drug used in the treatment of hematologic malignancies. We here investigated in solid tumor models whether lena can enhance the abscopal effect in double combination with hRT...
2024: Theranostics
https://read.qxmd.com/read/38644411/identification-and-validation-of-a-costimulatory-molecule-related-signature-to-predict-the-prognosis-for-uveal-melanoma-patients
#2
JOURNAL ARTICLE
Minyao Zhao, Yue Yu, Zhengyu Song
Uveal melanoma (UVM) is the most common primary tumor in adult human eyes. Costimulatory molecules (CMs) are important in maintaining T cell biological functions and regulating immune responses. To investigate the role of CMs in UVM and exploit prognostic signature by bioinformatics analysis. This study aimed to identify and validate a CMs associated signature and investigate its role in the progression and prognosis of UVM. The expression profile data of training cohort and validation cohort were downloaded from The Cancer Genome Atlas (TCGA) dataset and the Gene Expression Omnibus (GEO) dataset...
April 21, 2024: Scientific Reports
https://read.qxmd.com/read/38639358/urinary-proteomics-and-outcomes-in-heart-failure-with-preserved-ejection-fraction
#3
JOURNAL ARTICLE
Corinne Carland, Lei Zhao, Oday Salman, Jordana B Cohen, Payman Zamani, Qing Xiao, Ashok Dongre, Zhaoqing Wang, Christina Ebert, Danielle Greenawalt, Vanessa van Empel, A Mark Richards, Robert N Doughty, Ernst Rietzschel, Ali Javaheri, Yixin Wang, Peter H Schafer, Sarah Hersey, Leonidas N Carayannopoulos, Dietmar Seiffert, Ching-Pin Chang, David A Gordon, Francisco Ramirez-Valle, Douglas L Mann, Thomas P Cappola, Julio A Chirinos
BACKGROUND: Although several studies have addressed plasma proteomics in heart failure with preserved ejection fraction, limited data are available on the prognostic value of urinary proteomics. The objective of our study was to identify urinary proteins/peptides associated with death and heart failure admission in patients with heart failure with preserved ejection fraction. METHODS AND RESULTS: The study population included participants enrolled in TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial)...
April 19, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38635903/cd58-alterations-govern-antitumor-immune-responses-by-inducing-pd-l1-and-ido-in-diffuse-large-b-cell-lymphoma
#4
JOURNAL ARTICLE
Xiyue Xu, Yidan Zhang, Yaxiao Lu, Xiaoyan Zhang, Cuicui Zhao, Jiesong Wang, Qingpei Guan, Yingfang Feng, Meng Gao, Jingwei Yu, Zheng Song, Xia Liu, Zahra Golchehre, Lanfang Li, Weicheng Ren, Qiang Pan-Hammarström, Huilai Zhang, Xianhuo Wang
Recurrent abnormalities in immune surveillance-related genes affect the progression of diffuse large B-cell lymphoma (DLBCL) and modulate the response to therapeutic interventions. CD58 interacts with the CD2 receptor on T cells and natural killer (NK) cells and is recurrently mutated and deleted in DLBCL, suggesting it may play a role in regulating antitumor immunity. Herein, we comprehensively analyzed the genomic characteristics of CD58 through targeted next-generation sequencing, RNA-sequencing, whole-exome sequencing, and single-cell RNA-sequencing in patients with newly diagnosed DLBCL...
April 18, 2024: Cancer Research
https://read.qxmd.com/read/38633258/cd8-t-cells-are-necessary-for-improved-sepsis-survival-induced-by-cd28-agonism-in-immunologically-experienced-mice
#5
JOURNAL ARTICLE
Jerome C Anyalebechi, Yini Sun, Carolyn Davis, Maylene E Wagener, Zhe Liang, Eileen M Burd, Craig M Coopersmith, Mandy L Ford
INTRODUCTION: A hallmark of T cell dysregulation during sepsis is the downregulation of costimulatory molecules. CD28 is one of T cell costimulatory molecules significantly altered on memory T cells during sepsis. We recently showed that treatment with a αCD28 agonist in septic immunologically experienced mice led to improved survival. Therefore, here we aimed to identify the cell subset(s) necessary for the survival benefit observed in the context of CD28 agonism, and to further investigate the mechanism by which CD28 agonism improves sepsis survival in immunologically experienced mice...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38630291/comparative-performance-of-scfv-based-anti-bcma-car-formats-for-improved-t-cell-therapy-in-multiple-myeloma
#6
JOURNAL ARTICLE
Sophia Stock, Luisa Fertig, Adrian Gottschlich, Janina Dörr, Florian Märkl, Lina Majed, Vivien D Menkhoff, Ruth Grünmeier, Kai Rejeski, David M Cordas Dos Santos, Sebastian Theurich, Michael von Bergwelt-Baildon, Stefan Endres, Marion Subklewe, Sebastian Kobold
In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as intracellular costimulatory domain are in routine clinical use. As the CAR construct architecture can differentially impact performance and efficacy, the optimal construction of a BCMA-targeting CAR remains to be elucidated. Here, we hypothesized that varying the constituents of the CAR structure known to impact performance could shed light on how to improve established anti-BCMA CAR constructs...
April 17, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38625118/monophosphoryl-lipid-a-based-adjuvant-to-promote-the-immunogenicity-of-multivalent-meningococcal-polysaccharide-conjugate-vaccines
#7
JOURNAL ARTICLE
Kishore R Alugupalli
Activation of the adaptive immune system requires the engagement of costimulatory pathways in addition to B and T cell Ag receptor signaling, and adjuvants play a central role in this process. Many Gram-negative bacterial polysaccharide vaccines, including the tetravalent meningococcal conjugate vaccines (MCV4) and typhoid Vi polysaccharide vaccines, do not incorporate adjuvants. The immunogenicity of typhoid vaccines is due to the presence of associated TLR4 ligands in these vaccines. Because the immunogenicity of MCV4 is poor and requires boosters, I hypothesized that TLR4 ligands are absent in MCV4 and that incorporation of a TLR4 ligand-based adjuvant would improve their immunogenicity...
April 1, 2024: ImmunoHorizons
https://read.qxmd.com/read/38614824/murine-skeletal-muscle-satellite-cells-isolation-and-preliminary-study-on-regulation-in-immune-microenvironment-during-nurse-cells-formation-of-trichinella-spiralis-infection
#8
JOURNAL ARTICLE
Huifang Bai, Jing Ding, Saining Wang, Shuyan Zhang, Ning Jiang, Xiaoxia Wu, Guoliang Chen, Qianqian Dang, Mingyuan Liu, Bin Tang, Xuelin Wang
As an intracellular parasitic nematode, Trichinella spiralis (T. spiralis) can induce the formation of nurse cells (NC) in host muscles and keep it to survive within the NC for an extended period. The formation of NC is similar to muscle cell injury and repair which lead to the arrest of satellite cells in the G2/M phase and build a suitable parasitic environment for the muscle larvae of T. spiralis. However, the molecular mechanisms involved in skeletal muscle repair through skeletal muscle satellite cells (SMSC) and the host immune response during T...
April 6, 2024: Veterinary Parasitology
https://read.qxmd.com/read/38607026/an-ox-tra-ordinary-tale-the-role-of-ox40-and-ox40l-in-atopic-dermatitis
#9
REVIEW
Kaviyon Sadrolashrafi, Lily Guo, Robin Kikuchi, Audrey Hao, Rebecca K Yamamoto, Hannah C Tolson, Sara N Bilimoria, Danielle K Yee, April W Armstrong
The transmembrane glycoprotein OX40 receptor (OX40) and its ligand, OX40L, are instrumental modulators of the adaptive immune response in humans. OX40 functions as a costimulatory molecule that promotes T cell activation, differentiation, and survival through ligation with OX40L. T cells play an integral role in the pathogenesis of several inflammatory skin conditions, including atopic dermatitis (AD). In particular, T helper 2 (TH 2) cells strongly contribute to AD pathogenesis via the production of cytokines associated with type 2 inflammation (e...
March 28, 2024: Cells
https://read.qxmd.com/read/38593226/cb307-a-dual-targeting-costimulatory-humabody-vh-therapeutic-for-treating-psma-positive-tumors
#10
JOURNAL ARTICLE
Sophie Archer, Phillip M Brailey, Minjung Song, Phillip D Bartlett, Ines Figueiredo, Bora Gurel, Christina Guo, Verena Brucklacher-Waldert, H Lorraine Thompson, Jude Akinwale, Samantha E Boyle, Christine Rossant, Neil R Birkett, Julia Pizzey, Mark Maginn, James Legg, Richard Williams, Colette M Johnston, Philip Bland-Ward, Johann S de Bono, Andrew J Pierce
PURPOSE: CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as a cancer immunotherapeutic but development has been hampered by on-target off-tumor toxicities. A CD137 agonist targeted to the prostate-specific membrane antigen (PSMA), frequently and highly expressed on castration-resistant metastatic prostate cancer (mCRPC) tumor cells, could bring effective immunotherapy to this immunologically challenging to address disease...
April 15, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38589248/pd-1-downregulation-enhances-car-t-cell-antitumor-efficiency-by-preserving-a-cell-memory-phenotype-and-reducing-exhaustion
#11
JOURNAL ARTICLE
Wanyan Ouyang, Shi-Wei Jin, Nan Xu, Wei-Yang Liu, Han Zhao, Liuqingqing Zhang, Liqing Kang, Yi Tao, Yuanfang Liu, Yan Wang, Jin Wang, Feng Liu, Lei Yu, Zhiqiang Liu, Jian-Qing Mi
BACKGROUND: Despite the encouraging outcome of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) in managing relapsed or refractory multiple myeloma (RRMM) patients, the therapeutic side effects and dysfunctions of CAR-T cells have limited the efficacy and clinical application of this promising approach. METHODS: In this study, we incorporated a short hairpin RNA cassette targeting PD-1 into a BCMA-CAR with an OX-40 costimulatory domain...
April 8, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38572648/single-cell-rna-sequencing-reveals-an-immune-landscape-of-cd4-t-cells-in-coronary-culprit-plaques-with-acute-coronary-syndrome-in-humans
#12
JOURNAL ARTICLE
Shintaro Takeda, Takuo Emoto, Tomoya Yamashita, Hiroyuki Yamamoto, Tomofumi Takaya, Takahiro Sawada, Takeshi Yoshida, Masatoshi Inoue, Yuya Suzuki, Tomoyo Hamana, Taishi Inoue, Masayuki Taniguchi, Naoto Sasaki, Hiromasa Otake, Takenao Ohkawa, Tomoyuki Furuyashiki, Hiroya Kawai, Ken-Ichi Hirata
BACKGROUND: Acute coronary syndrome (ACS) involves plaque-related thrombosis, causing primary ischemic cardiomyopathy or lethal arrhythmia. We previously demonstrated a unique immune landscape of myeloid cells in the culprit plaques causing ACS by using single-cell RNA sequencing. Here, we aimed to characterize T cells in a single-cell level, assess clonal expansion of T cells, and find a therapeutic target to prevent ACS. METHODS: We obtained the culprit lesion plaques from 4 patients with chronic coronary syndrome (chronic coronary syndrome plaques) and the culprit lesion plaques from 3 patients with ACS (ACS plaques) who were candidates for percutaneous coronary intervention with directional coronary atherectomy...
April 4, 2024: Arteriosclerosis, Thrombosis, and Vascular Biology
https://read.qxmd.com/read/38570084/jaml-promotes-the-antitumor-role-of-tumor-resident-cd8-t-cells-by-facilitating-their-innate-like-function-in-human-lung-cancer
#13
JOURNAL ARTICLE
Zhixing Hao, Zhongwei Xin, Yongyuan Chen, Zheyu Shao, Wei Lin, Wenxuan Wu, Mingjie Lin, Qinyuan Liu, Di Chen, Dang Wu, Pin Wu
Tissue-resident memory CD8+T cells (CD8+TRMs) are thought to play a crucial role in cancer immunosurveillance. However, the characteristics of CD8+TRMs in the tumor microenvironment (TME) of human non-small cell lung cancer (NSCLC) remain unclear. Here, we report that CD8+TRMs accumulate explicitly and exhibit a unique gene expression profile in the TME of NSCLC. Interestingly, these tumor-associated CD8+TRMs uniquely exhibit an innate-like phenotype. Importantly, we found that junction adhesion molecule-like (JAML) provides an alternative costimulatory signal to activate tumor-associated CD8+TRMs via combination with cancer cell-derived CXADR (CXADR Ig-like cell adhesion molecule)...
April 1, 2024: Cancer Letters
https://read.qxmd.com/read/38567291/the-effect-of-abatacept-on-t-cell-activation-is-not-long-lived-in-vivo
#14
JOURNAL ARTICLE
Larissa C da Rosa, Hannah E Scales, Robert A Benson, James M Brewer, Iain B McInnes, Paul Garside
Abatacept, a co-stimulatory blocker comprising the extracellular portion of human CTLA-4 linked to the Fc region of IgG1, is approved for the treatment of rheumatoid arthritis. By impairing the interaction between CD28 on T cells and CD80/CD86 on APCs, its mechanisms of action include the suppression of follicular T helper cells (preventing the breach of self-tolerance in B cells), inhibition of cell cycle progression holding T cells in a state described as 'induced naïve' and reduction in DC conditioning...
2024: Discov Immunol
https://read.qxmd.com/read/38564022/activation-of-sting-by-the-novel-liposomal-tlc388-enhances-the-therapeutic-response-to-anti-pd-1-antibodies-in-combination-with-radiotherapy
#15
JOURNAL ARTICLE
Jhen-Yu Chen, Po-Yu Lin, Wei-Ze Hong, Pei-Chen Yang, Shu-Fen Chiang, Hsin-Yu Chang, Tao-Wei Ke, Ji-An Liang, William Tzu-Liang Chen, K S Clifford Chao, Kevin Chih-Yang Huang
Current immune checkpoint inhibiters (ICIs) have contrasting clinical results in poorly immunogenic cancers such as microsatellite-stable colorectal cancer (MSS-CRC). Therefore, understanding and developing the combinational therapeutics for ICI-unresponsive cancers is critical. Here, we demonstrated that the novel topoisomerase I inhibitor TLC388 can reshape the tumor immune landscape, corroborating their antitumor effects combined with radiotherapy as well as immunotherapy. We found that TLC388 significantly triggered cytosolic single-stranded DNA (ssDNA) accumulation for STING activation, leading to type I interferons (IFN-Is) production for increased cancer immunogenicity to enhance antitumor immunity...
April 2, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38563577/engineering-cd3-cd137-dual-specificity-into-a-dll3-targeted-t-cell-engager-enhances-t-cell-infiltration-and-efficacy-against-small-cell-lung-cancer
#16
JOURNAL ARTICLE
Hirofumi Mikami, Shu Feng, Yutaka Matsuda, Shinya Ishii, Sotaro Naoi, Yumiko Azuma, Hiroaki Nagano, Kentaro Asanuma, Yoko Kayukawa, Toshiaki Tsunenari, Shogo Kamikawaji, Ryutaro Iwabuchi, Junko Shinozuka, Masaki Yamazaki, Haruka Kuroi, Samantha Shu Wen Ho, Siok Wan Gan, Priyanka Chichili, Chai Ling Pang, Chiew Ying Yeo, Shun Shimizu, Naoka Hironiwa, Yasuko Kinoshita, Yuichiro Shimizu, Akihisa Sakamoto, Masaru Muraoka, Noriyuki Takahashi, Tatsuya Kawa, Hirotake Shiraiwa, Futa Mimoto, Kenji Kashima, Mika Kamata-Sakurai, Shumpei Ishikawa, Hiroyuki Aburatani, Takehisa Kitazawa, Tomoyuki Igawa
Small-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all patients with SCLC are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation...
April 1, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38558120/engineering-cd3-cd137-dual-specificity-into-a-dll3-targeted-t-cell-engager-enhances-t-cell-infiltration-and-efficacy-against-small-cell-lung-cancer
#17
JOURNAL ARTICLE
Hirofumi Mikami, Shu Feng, Yutaka Matsuda, Shinya Ishii, Sotaro Naoi, Yumiko Azuma, Hiroaki Nagano, Kentaro Asanuma, Yoko Kayukawa, Toshiaki Tsunenari, Shogo Kamikawaji, Ryutaro Iwabuchi, Junko Shinozuka, Masaki Yamazaki, Haruka Kuroi, Samantha Shu Wen Ho, Siok Wan Gan, Priyanka Chichili, Chai Ling Pang, Chiew Ying Yeo, Shun Shimizu, Naoka Hironiwa, Yasuko Kinoshita, Yuichiro Shimizu, Akihisa Sakamoto, Masaru Muraoka, Noriyuki Takahashi, Tatsuya Kawa, Hirotake Shiraiwa, Futa Mimoto, Kenji Kashima, Mika Kamata-Sakurai, Shumpei Ishikawa, Hiroyuki Aburatani, Takehisa Kitazawa, Tomoyuki Igawa
Small cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICIs) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all SCLC patients are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation...
March 20, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38555445/peg-ifn%C3%AE-combined-with-hepatitis-b-vaccination-contributes-to-hbsag-seroconversion-and-improved-immune-function
#18
JOURNAL ARTICLE
Yisi Liu, Shan Ren, Lina Ma, Xiao Lin, Junfeng Lu, Zhenhuan Cao, Sujun Zheng, Zhongjie Hu, Xiaoxue Xu, Xinyue Chen
PURPOSE: The purpose of this study was to investigate immunological variations between a group that received the hepatitis B vaccine and a non-vaccine group. We focused on a cohort that achieved HBsAg seroclearance after Peg-IFNα treatment of CHB. METHODS: We enrolled twenty-eight individuals who achieved HBsAg seroclearance after Peg-IFNα treatment. They were divided into two groups: a vaccine group (n = 14) and a non-vaccine group (n = 14)...
March 30, 2024: Virology Journal
https://read.qxmd.com/read/38543954/differential-immune-response-patterns-induced-by-anionic-and-cationic-lipid-adjuvants-in-intranasal-anti-influenza-immunization
#19
JOURNAL ARTICLE
Anirban Sengupta, Noha Al-Otaibi, Claudia Devito, Francisca Lottersberger, Jorma Hinkula
Currently, vaccine development against different respiratory diseases is at its peak. It is of utmost importance to find suitajble adjuvants that can increase the potency of the vaccine candidates. This study aimed to determine the systemic and splenic immune mechanisms in mice models induced by anionic and cationic lipid adjuvants in the presence of the vaccine-candidate influenza antigen hemagglutinin (HA). In the presence of the HA antigen, the cationic adjuvant (N3) increased conventional dendritic cell 1 (cDC1) abundance with enhanced MHCI and CD80-CD86 costimulatory marker expression, and significantly higher CD8T and Th17 populations with enhanced interferon-gamma (IFNγ) expression in CD8T and CD4T populations...
March 18, 2024: Vaccines
https://read.qxmd.com/read/38541064/exploring-costimulatory-blockade-based-immunologic-strategies-in-transplantation-are-they-a-promising-immunomodulatory-approach-for-organ-and-vascularized-composite-allotransplantation
#20
REVIEW
Andreea Grosu-Bularda, Florin-Vlad Hodea, Dragos Zamfirescu, Alexandru Stoian, Răzvan Nicolae Teodoreanu, Ioan Lascăr, Cristian Sorin Hariga
The field of transplantation, including the specialized area of vascularized composite allotransplantation (VCA), has been transformed since the first hand transplant in 1998. The major challenge in VCA comes from the need for life-long immunosuppressive therapy due to its non-vital nature and a high rate of systemic complications. Ongoing research is focused on immunosuppressive therapeutic strategies to avoid toxicity and promote donor-specific tolerance. This includes studying the balance between tolerance and effector mechanisms in immune modulation, particularly the role of costimulatory signals in T lymphocyte activation...
March 20, 2024: Journal of Personalized Medicine
keyword
keyword
96002
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.